Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview

被引:21
|
作者
Butreddy, Arun [1 ]
Nyavanandi, Dinesh [1 ]
Narala, Sagar [1 ]
Austin, Fischer [1 ]
Bandari, Suresh [1 ]
机构
[1] Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, Oxford, MS 38677 USA
关键词
Hot melt extrusion; abuse; opioids; manipulation; abuse deterrent formulations; polymer; EXTENDED-RELEASE; TAMPER-RESISTANT; DELIVERY; OPIOIDS; DESIGN; EXCIPIENTS; ETHANOL; PELLETS; STARCH;
D O I
10.2174/1567201817999200817151601
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The misuse, abuse, and illicit use of prescription opioid analgesics is a global public health concern. However, there are many viable therapeutic options for the treatment of patients with chronic pain. Both intact and manipulated opioid drug products are abused by various routes such as oral, nasal, and injection, which may lead to overdose, drug addiction, and even death. To combat the abuse of these medications, regulatory agencies and pharmaceutical companies are switching their interest towards developing Abuse Deterrent Formulations (ADFs), with the intent to deter the abuse of opioid products to a maximum extent. There are several manufacturing strategies implemented in an attempt to develop ADFs. An example includes matrix tablets of high molecular weight polymers such as polyethylene oxide. The scalable and continuous manufacturing techniques, such as Hot-Melt Extrusion (HME), is increasingly accepted by pharmaceutical companies to advance the development and manufacturing of ADFs. The application of the 11ME technique in the development of ADFs may overcome the challenges of opioid analgesic formulation development and provide improved protection against misuse and abuse, while also ensuring access to safe and effective use in patients with chronic pain. This review deals with a brief overview of strategies, with emphasis on HME to deter opioid abuse, in vitro characterization methods, commonly used excipients in the development of ADFs, and regulatory standards to meet the requirements of ADFs.
引用
收藏
页码:4 / 18
页数:15
相关论文
共 50 条
  • [1] Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion
    Xiaoming Xu
    Akhtar Siddiqui
    Charudharshini Srinivasan
    Adil Mohammad
    Ziyaur Rahman
    Maxwell Korang-Yeboah
    Xin Feng
    Mansoor Khan
    Muhammad Ashraf
    AAPS PharmSciTech, 20
  • [2] Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion
    Xu, Xiaoming
    Siddiqui, Akhtar
    Srinivasan, Charudharshini
    Mohammad, Adil
    Rahman, Ziyaur
    Korang-Yeboah, Maxwell
    Feng, Xin
    Khan, Mansoor
    Kshraf, Muhammad
    AAPS PHARMSCITECH, 2019, 20 (06)
  • [3] Abuse-Deterrent Opioid Formulations
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (16): : 1744 - 1745
  • [4] Abuse-deterrent Opioid Formulations
    Litman, Ronald S.
    Pagan, Olivia H.
    Cicero, Theodore J.
    ANESTHESIOLOGY, 2018, 128 (05) : 1015 - 1026
  • [5] Abuse-Deterrent Opioid Formulations
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1476): : 119 - 121
  • [6] An overview of prodrug technology and its application for developing abuse-deterrent opioids
    Gudin, Jeffrey A.
    Nalamachu, Srinivas R.
    POSTGRADUATE MEDICINE, 2016, 128 (01) : 97 - 105
  • [7] Challenges in the development of prescription opioid abuse-deterrent formulations
    Katz, Nathaniel P.
    Adams, Edgar H.
    Chilcoat, Howard
    Colucci, Robert D.
    Comer, Sandra D.
    Goliber, Philip
    Grudzinskas, Charles
    Jasinski, Donald
    Lande, Stephen D.
    Passik, Steven D.
    Schnoll, Sidney H.
    Sellers, Edward
    Travers, Debra
    Weiss, Roger
    CLINICAL JOURNAL OF PAIN, 2007, 23 (08): : 648 - 660
  • [8] FDA: guidance on development of abuse-deterrent opioid formulations
    不详
    FORMULARY, 2013, 48 (02) : 84 - 84
  • [9] Abuse-Deterrent Formulations of Prescription Opioids
    Dart, Richard C.
    Severtson, S. Geoff
    Green, Jody L.
    JAMA PSYCHIATRY, 2015, 72 (08) : 849 - 849
  • [10] Abuse-deterrent opioid analgesic formulations: technology, evaluation, and labeling
    Haddox, J.
    JOURNAL OF PAIN, 2014, 15 (04): : S42 - S42